A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)
This is an open-label phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable intermediate stage HCC.
Primary Objective * Assess progression free survival (PFS) per RECIST 1.1 Secondary Objectives * Assess safety and tolerability of Y-90 TARE combined with atezolizumab and bevacizumab in patients with HCC. * Assess the progression free survival (PFS) per mRECIST * Assess Time to Progression (TTP) per RECIST 1.1 and mRECIST * Assess Overall response rate (ORR) per RECIST 1.1 and mRECIST * Assess Overall survival (OS) * Evaluate PROs of physical functioning, role functioning, social functioning, and global health status/quality of life experienced by patients receiving Y-90 TARE and bevacizumab plus atezolizumab treatment.
Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Not Applicable (); Yttrium-90 ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.